Table 2 Mean change in Hb levels over time by treatment arm (TARGET, MOBILITY, and MONARCH)
Hb (g/L) | Baseline | Mean change from baseline to 24 weeks | Mean change from baseline to 52 weeks |
|---|---|---|---|
TARGET | |||
 Placebo + DMARD | 126.6 | − 0.3 | – |
 Sarilumab 150 mg q2w + DMARD | 128.1 | + 8.0 | – |
 Sarilumab 200 mg q2w + DMARD | 125.7 | + 9.0 | – |
MOBILITY | |||
 Placebo + MTX | 127.0 | − 0.3 | − 0.6 |
 Sarilumab 150 mg + MTX | 125.6 | + 7.9 | + 9.1 |
 Sarilumab 200 mg + MTX | 126.6 | + 8.2 | + 10.0 |
MONARCH | |||
 Adalimumab 40 mg q2w | 129.5 | + 1.1 | – |
 Sarilumab 200 mg q2w | 130.1 | + 6.0 | – |